Merck's Experimental HIV Prevention Pill Could Be Manufactured for Under $5 Annually, Researchers Say

Researchers have published an analysis showing that Merck's experimental HIV prevention pill MK-8527 could be mass produced for less than $5 per patient per year, prompting advocates to urge the company to license generic production for global access. The drug is currently undergoing late-stage clinical trials with results expected in the latter half of 2027, following promising mid-stage results released in summer 2025 that showed MK-8527 could protect against HIV infection within 24 hours and was both safe and effective. The pill works through a novel mechanism according to Merck. Advocates argue the remarkably low manufacturing cost should make it easier for Merck to license the drug to low- and middle-income countries where HIV prevention access remains limited.

Low-cost manufacturing potential of Merck's HIV prevention pill

• ▪Merck's experimental HIV prevention pill MK-8527 could be mass produced for less than $5 per patient per year according to a new analysis.

Clinical development and mechanism of MK-8527

• ▪MK-8527 works in a novel way according to Merck.
• ▪Merck released mid-stage results for MK-8527 in summer 2025 showing the drug holds promise.
• ▪MK-8527 mid-stage study results found the pill could protect against HIV infection within 24 hours after being taken.
• ▪MK-8527 is currently undergoing a pair of late-stage clinical trials expected to determine whether the medicine can lower HIV transmission when given to people at high risk of infection.
• ▪MK-8527 mid-stage study results showed the drug was safe and effective.
• ▪Results from MK-8527's late-stage clinical trials are due in the latter half of 2027 according to postings on ClinicalTrials.gov.

Access and licensing implications for low-income countries

• ▪Advocates argue the low manufacturing cost of MK-8527 means Merck should find it easier to license the drug so that low- and middle-income countries can gain easy access.

Perspective of HIV prevention advocates

• ▪The low manufacturing cost of under $5 per year for MK-8527 makes licensing to low- and middle-income countries more feasible according to advocates.
• ▪Merck should urgently begin licensing generic production of MK-8527 to improve global access according to advocates.

1 source